Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Q&A Exclusive: FDA Commissioner Talks About His Tenure, Recruiting And LDTs

Executive Summary

US FDA Commissioner Scott Gottlieb sat down with Medtech Insight and Pink Sheet reporters for an exclusive chat about his ongoing regulatory work and plans for the future.

You may also be interested in...



FDA Pathway Options Are Growing For Diagnostics, FDA's Gottlieb Tells Commercial Labs

While lab-developed test (LDTs) remain under a US FDA enforcement discretion policy, the agency is working on several fronts to offer appealing regulatory pathways for advanced diagnostic services, FDA Commissioner Scott Gottlieb told American Clinical Laboratory Association members.

US FDA Chief Favors LDT Approach In Bucshon-DeGette Bill

FDA Commissioner Scott Gottlieb told Reps. Larry Bucshon, R-Ind. and Diana DeGette, D-Colo., that he favors their approach to regulating laboratory developed tests, as spelled out in their draft Diagnostics Accuracy and Innovation Act bill released last spring. The traditional device approval process is a "poor fit" for LDTs, he added.

A New York Minute: US FDA Leverages State's Health Department To Expedite NGS Reviews

The agency authorized a next-generation sequencing tumor profiling system that leverages the New York State Department of Health to speed future clearances.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

MT121736

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel